These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 27102439)

  • 1. The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma.
    Boregowda RK; Medina DJ; Markert E; Bryan MA; Chen W; Chen S; Rabkin A; Vido MJ; Gunderson SI; Chekmareva M; Foran DJ; Lasfar A; Goydos JS; Cohen-Solal KA
    Oncotarget; 2016 May; 7(20):29689-707. PubMed ID: 27102439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion.
    Boregowda RK; Olabisi OO; Abushahba W; Jeong BS; Haenssen KK; Chen W; Chekmareva M; Lasfar A; Foran DJ; Goydos JS; Cohen-Solal KA
    Cancer Lett; 2014 Jun; 348(1-2):61-70. PubMed ID: 24657655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
    Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
    Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification.
    Dugo M; Nicolini G; Tragni G; Bersani I; Tomassetti A; Colonna V; Del Vecchio M; De Braud F; Canevari S; Anichini A; Sensi M
    Oncotarget; 2015 Mar; 6(7):5118-33. PubMed ID: 25742786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.
    Capaldo BJ; Roller D; Axelrod MJ; Koeppel AF; Petricoin EF; Slingluff CL; Weber MJ; Mackey AJ; Gioeli D; Bekiranov S
    PLoS One; 2015; 10(9):e0138210. PubMed ID: 26405815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Runx2 in crosstalk between Mek/Erk and PI3K/Akt signaling in MCF-10A cells.
    Tandon M; Chen Z; Pratap J
    J Cell Biochem; 2014 Dec; 115(12):2208-17. PubMed ID: 25147082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
    Miao B; Ji Z; Tan L; Taylor M; Zhang J; Choi HG; Frederick DT; Kumar R; Wargo JA; Flaherty KT; Gray NS; Tsao H
    Cancer Discov; 2015 Mar; 5(3):274-87. PubMed ID: 25542448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An essential role of discoidin domain receptor 2 (DDR2) in osteoblast differentiation and chondrocyte maturation via modulation of Runx2 activation.
    Zhang Y; Su J; Yu J; Bu X; Ren T; Liu X; Yao L
    J Bone Miner Res; 2011 Mar; 26(3):604-17. PubMed ID: 20734453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression.
    Cohen-Solal KA; Boregowda RK; Lasfar A
    Mol Cancer; 2015 Jul; 14():137. PubMed ID: 26204939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells.
    Lee C
    Mol Med Rep; 2015 Jul; 12(1):1485-92. PubMed ID: 25815442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RT-PCR-based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target.
    Thamm DH; Huelsmeyer MK; Mitzey AM; Qurollo B; Rose BJ; Kurzman ID
    Melanoma Res; 2010 Feb; 20(1):35-42. PubMed ID: 19949352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth hormone attenuates the transcriptional activity of Runx2 by facilitating its physical association with Stat3beta.
    Ziros PG; Georgakopoulos T; Habeos I; Basdra EK; Papavassiliou AG
    J Bone Miner Res; 2004 Nov; 19(11):1892-904. PubMed ID: 15476590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.
    Prahallad A; Heynen GJ; Germano G; Willems SM; Evers B; Vecchione L; Gambino V; Lieftink C; Beijersbergen RL; Di Nicolantonio F; Bardelli A; Bernards R
    Cell Rep; 2015 Sep; 12(12):1978-85. PubMed ID: 26365186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential.
    Wu X; Zhou J; Rogers AM; Jänne PA; Benedettini E; Loda M; Hodi FS
    Melanoma Res; 2012 Apr; 22(2):123-32. PubMed ID: 22343486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional upregulation of DDR2 by ATF4 facilitates osteoblastic differentiation through p38 MAPK-mediated Runx2 activation.
    Lin KL; Chou CH; Hsieh SC; Hwa SY; Lee MT; Wang FF
    J Bone Miner Res; 2010 Nov; 25(11):2489-503. PubMed ID: 20564243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Potential Role of RUNX2- RUNT Domain in Modulating the Expression of Genes Involved in Bone Metastases: An In Vitro Study with Melanoma Cells.
    Deiana M; Dalle Carbonare L; Serena M; Cheri S; Mutascio S; Gandini A; Innamorati G; Lorenzi P; Cumerlato M; Bertacco J; Antoniazzi F; Romanelli MG; Mottes M; Zipeto D; Valenti MT
    Cells; 2020 Mar; 9(3):. PubMed ID: 32204402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
    Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
    Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the Interplay of RUNX2 and CXCR4 in Melanoma Progression.
    Dalle Carbonare L; Minoia A; Vareschi A; Piritore FC; Zouari S; Gandini A; Meneghel M; Elia R; Lorenzi P; Antoniazzi F; Pessoa J; Zipeto D; Romanelli MG; Guardavaccaro D; Valenti MT
    Cells; 2024 Feb; 13(5):. PubMed ID: 38474372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth.
    Yoshida M; Selvan S; McCue PA; DeAngelis T; Baserga R; Fujii A; Rui H; Mastrangelo MJ; Sato T
    Pigment Cell Melanoma Res; 2014 Mar; 27(2):297-308. PubMed ID: 24354797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.